Already have an account? Sign In
Respicardia, founded in 2006 and headquartered in Minnetonka, Minnesota, is a medical technology company specializing in implantable therapies for respiratory and cardiovascular health. Their flagship product, the remede System, is an innovative implantable stimulation device designed to restore regular breathing patterns during sleep for patients with central sleep apnea.
Since its inception, Respicardia has raised a total of $152.82 million in funding, demonstrating significant investor interest in their groundbreaking technology. The company's focus on addressing sleep apnea, a widespread health concern, positions them as a potentially attractive investment opportunity in the medical device sector.
It's important to note that on April 12th, 2021, Respicardia was acquired by ZOLL Medical Corporation. The terms of this acquisition were not publicly disclosed. This acquisition may have implications for any potential future public offering of Respicardia stock.
As of now, there is no concrete information available regarding Respicardia's plans for an initial public offering (IPO). The company's current status as a subsidiary of ZOLL Medical Corporation likely impacts any decisions regarding going public. Investors interested in Respicardia should keep in mind that the company's future, including any potential IPO, is now closely tied to ZOLL Medical Corporation's strategic decisions.
Given the lack of official announcements or credible reports about Respicardia's IPO prospects, it would be premature to speculate on the likelihood or timing of such an event. As always, potential investors should conduct thorough research and consider multiple factors before making investment decisions.
Already have an account? Sign In
While Respicardia's IPO prospects remain uncertain, investors interested in innovative medical technology companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the healthcare and medical device sectors. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging industry pioneers like Respicardia before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.